Although monotherapies are observed to be ineffective in managing cancer progression [167], phase-II studies of these two compounds showed promising results in combinational therapy to combat multiple types of advanced or metastatic cancer, including ER+/HER2- breast cancer [169], triple-negative breast cancer [170], gastric cancer [171], and prostate cancer [172]. This evidence concerns the gene ESR1 and breast cancer.